Does Medicare Advantage Cover Evenity (Romosozumab)?

Why Evenity Falls Under Part B, Not Part D

Evenity is administered by a healthcare professional in a clinic or infusion center. That distinction determines its coverage pathway. Medicare Part B covers drugs that require physician supervision for administration, while Part D covers self-administered oral and injectable medications filled at a pharmacy 1.

Because romosozumab is given as two subcutaneous injections (each 105 mg) by a provider during an office visit, it falls squarely under Part B. This matters for beneficiaries: Part B drug coverage follows a different cost-sharing structure than the tiered copays of a Part D formulary. Under original Medicare Part B, the standard cost-share is 20% of the Medicare-approved amount after the annual Part B deductible ($257 in 2025). Medicare Advantage plans must offer at least equivalent Part B coverage, though many apply different cost-sharing structures or require prior authorization before approving the first dose.

Some Medicare Advantage plans with integrated Part B drug management programs (known as Part B step therapy programs, authorized by CMS since 2019) may impose additional utilization management. Check your plan's Evidence of Coverage document for the specific Evenity policy.

Prior Authorization Criteria Across Major Carriers

Nearly every Medicare Advantage carrier requires prior authorization for Evenity. The clinical criteria are broadly consistent because they follow the FDA-approved labeling and national coverage guidance, but each plan can set its own specifics.

Common requirements include a confirmed diagnosis of osteoporosis with a DXA T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip. Plans also accept a history of fragility fracture (vertebral compression fracture, hip fracture, or other low-trauma fracture) as qualifying evidence. A FRAX 10-year major osteoporotic fracture probability exceeding 20% may substitute for T-score criteria in some plan protocols.

Most carriers require documentation that the patient has tried or has a contraindication to at least one first-line antiresorptive agent. Alendronate (Fosamax), risedronate (Actonel), or denosumab (Prolia) are the most commonly cited step-therapy prerequisites. The prescriber must attest that the patient remains at high or very high fracture risk despite, or is intolerant of, these therapies.

Plans also require confirmation that the patient has no history of myocardial infarction or stroke within the past 12 months, consistent with the boxed warning on the Evenity label [2]. The prescribing physician must document cardiovascular risk assessment before the first injection.

Authorization is typically granted for the full 12-month treatment course (12 doses) but may be issued in shorter intervals (3 or 6 months) with reauthorization required to continue.

Step Therapy Requirements

Step therapy is the norm. Most Medicare Advantage plans classify Evenity as a second-line or third-line agent, requiring failure of or intolerance to at least one bisphosphonate before approval.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines do endorse romosozumab as a first-line option for patients at "very high" fracture risk. Very high risk, per AACE, includes patients with a recent osteoporotic fracture (within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while on drugs causing skeletal harm (such as long-term glucocorticoids), or a T-score below -3.0 [3].

If your clinical scenario matches the AACE very-high-risk category, your physician can submit documentation requesting a step-therapy exception. Plans are required by CMS to have an exceptions process. The key is to frame the request around fracture imminence: a 2020 analysis published in the Journal of Bone and Mineral Research found that the risk of a second vertebral fracture is highest in the first 12 months following an initial fracture, supporting the case for anabolic-first therapy without waiting for a bisphosphonate trial 4.

Submit the step-therapy exception alongside the prior authorization request. Include the DXA report, fracture imaging, FRAX score, and a letter explaining why delaying anabolic therapy to complete a bisphosphonate trial would expose the patient to unacceptable fracture risk.

What the ARCH Trial Showed About Fracture Reduction

The ARCH trial (N=4,093) compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a fragility fracture 5. At 24 months, the romosozumab-to-alendronate sequence reduced the risk of new vertebral fracture by 48% compared with alendronate alone (relative risk 0.52 to 95% CI 0.40 to 0.68). Non-vertebral fracture risk fell by 19% (hazard ratio 0.81 to 95% CI 0.66 to 0.99).

These numbers matter for prior authorization appeals. A 48% relative risk reduction is the strongest fracture-reduction signal among any osteoporosis drug studied head-to-head against an active comparator rather than placebo. The FRAME trial (N=7,180) had earlier shown a 73% reduction in new vertebral fractures versus placebo at 12 months, but ARCH provided the clinically relevant active-comparator data that influenced the FDA label [6].

The cardiovascular safety signal in ARCH is what generated the black box warning. Adjudicated major adverse cardiovascular events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group at 12 months. This difference was not statistically significant, but it was sufficient for the FDA to add a warning and to make cardiovascular risk assessment a prerequisite for prescribing [2].

Dr. Felicia Cosman, then at Columbia University and a lead investigator on the romosozumab program, stated: "The clinical profile of romosozumab supports its use as a first-line anabolic agent in patients at very high fracture risk, provided cardiovascular history is carefully evaluated" [5].

Out-of-Pocket Costs Under Medicare Advantage

The wholesale acquisition cost (WAC) of Evenity is approximately $1,825 per monthly dose. A full 12-month course totals roughly $21,900 at list price. Under original Medicare Part B, patients owe 20% coinsurance after the annual deductible, which works out to approximately $365 per injection, or about $4,380 for the full treatment course.

Medicare Advantage plans may alter this cost structure. Some plans apply a fixed copay per Part B drug administration rather than percentage-based coinsurance. Others cap out-of-pocket maximums for Part B services. The CMS-mandated annual out-of-pocket maximum for Medicare Advantage in-network services is $8 to 850 in 2025, and Part B drug costs count toward this cap 7.

Supplemental Medigap coverage (Plans F, G, or N for those enrolled in Original Medicare) typically covers the 20% Part B coinsurance. Beneficiaries enrolled in a Medicare Advantage plan do not use Medigap, so their cost-sharing depends entirely on the MA plan's benefit design.

Amgen, the manufacturer, offers a patient assistance program (Amgen Assist 360) for eligible patients, but federal law prohibits manufacturer copay cards from being used by Medicare beneficiaries. Patients with financial hardship may qualify for the Amgen Safety Net Foundation, a separate 501(c)(3) charity that provides free drug to qualifying individuals regardless of insurance status 8.

The Bone Health and Osteoporosis Foundation and the HealthWell Foundation may also offer copay assistance grants for Medicare patients prescribed bone-anabolic agents, though fund availability fluctuates.

How to Appeal a Medicare Advantage Denial

Medicare Advantage plans must follow a structured five-level appeals process mandated by CMS 9.

Level 1: Plan reconsideration. File within 60 days of the denial. Include updated clinical documentation, the most recent DXA scan, fracture imaging (X-ray or CT), FRAX score printout, and a peer-reviewed letter of medical necessity from the treating physician. Reference AACE or Endocrine Society guidelines to establish that romosozumab is the standard of care for the patient's fracture risk profile. The plan must respond within 30 days for a standard request or 72 hours for an expedited request when delay could cause serious health harm.

Level 2: Independent Review Entity (IRE). If the plan upholds its denial, the case automatically forwards to an IRE (currently Maximus Federal Services). The IRE reviews the case independently and must decide within 30 days (standard) or 72 hours (expedited).

Level 3: Office of Medicare Hearings and Appeals (OMHA). An Administrative Law Judge hearing is available if the amount in controversy meets the threshold ($180 in 2025). Given that the 12-month cost of Evenity exceeds $20,000, this threshold is easily met.

Levels 4 and 5 involve the Medicare Appeals Council and federal district court, respectively. Very few osteoporosis drug denials reach these stages.

The most effective appeal strategy is to submit a comprehensive packet at Level 1. Include: (a) the ARCH trial citation demonstrating superiority over alendronate [5], (b) AACE guideline language classifying the patient as very high risk [3], (c) documentation of prior therapy failure or intolerance, (d) a cardiovascular risk clearance note, and (e) any imaging showing existing fractures with dates.

Expedited appeals are appropriate when the patient has sustained a recent fracture and delay in initiating anabolic therapy could lead to additional fractures. The Endocrine Society 2020 Clinical Practice Guideline recommends anabolic therapy before antiresorptive therapy in patients at very high fracture risk, providing guideline-level support for expedited review [10].

Romosozumab vs. Other Bone-Anabolic Agents on Medicare

Two other anabolic osteoporosis agents compete with romosozumab for Medicare coverage: teriparatide (Forteo) and abaloparatide (Tymlos). Both are PTH/PTHrP analogs administered as daily self-injections, meaning they fall under Part D rather than Part B.

This coverage split creates different cost dynamics. Under Part D, patients face tiered copays and the coverage gap ("donut hole"). Forteo and Tymlos often sit on specialty tiers with 25-33% coinsurance in the coverage gap. Romosozumab under Part B avoids the Part D coverage gap entirely, but the 20% coinsurance can still be substantial without supplemental coverage.

Head-to-head efficacy data between romosozumab and teriparatide are limited. The STRUCTURE trial (N=436) compared romosozumab vs. teriparatide in postmenopausal women who had previously taken bisphosphonates, measuring total hip BMD at 12 months 11. Romosozumab increased total hip BMD by 2.6% vs. 0.6% with teriparatide. Lumbar spine gains were 9.8% vs. 5.4%.

Dr. Benjamin Leder of Massachusetts General Hospital, who led the STRUCTURE trial, noted: "In patients transitioning from bisphosphonate therapy, romosozumab produces substantially greater gains in hip BMD, which is the site most relevant to preventing the most devastating osteoporotic fractures" [11].

Treatment duration differs as well. Romosozumab is approved for a maximum of 12 monthly doses. Teriparatide and abaloparatide are approved for up to 24 months. All three require transition to an antiresorptive agent (typically a bisphosphonate or denosumab) after the anabolic phase to maintain bone density gains. Discontinuation without antiresorptive follow-up leads to rapid bone loss within 12 months.

Specific Carrier Policies to Check

Medicare Advantage is not a single plan. Over 3,900 MA plans operate across the United States, offered by carriers including UnitedHealthcare, Humana, Aetna (CVS Health), Cigna, Blue Cross Blue Shield affiliates, Kaiser Permanente, and Centene (WellCare). Each plan files its own Part B utilization management criteria with CMS.

To find your plan's Evenity coverage policy:

1. Call the plan's prior authorization department using the number on the back of your member ID card.
2. Ask specifically about "Part B step therapy and prior authorization for J3111" (the HCPCS code for romosozumab injection).
3. Request a copy of the plan's clinical coverage criteria for romosozumab in writing.
4. Ask whether the plan participates in the CMS Part B step therapy demonstration or applies its own internal utilization management.

Your physician's billing office can also submit a pre-service coverage determination request, which gives a written yes-or-no answer before the first injection is administered. This avoids surprise denials after treatment has already begun.

Cardiovascular Screening Before Coverage Approval

The FDA black box warning on Evenity states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death [2]. The labeling contraindicates use in patients who have had an MI or stroke within the preceding 12 months and advises against use in patients at high cardiovascular risk.

Medicare Advantage plans translate this warning into coverage requirements. Expect the prior authorization form to ask whether the patient has had a cardiovascular event in the past year, whether a cardiovascular risk assessment has been performed, and whether the benefits of fracture risk reduction outweigh the cardiovascular risk for this specific patient.

In practice, this means the prescribing clinician should document a recent lipid panel, blood pressure readings, and any history of coronary artery disease, cerebrovascular disease, or peripheral arterial disease. Some plans require a cardiology clearance note for patients with any documented cardiovascular disease, even if the most recent event was more than 12 months ago.

A post hoc analysis of pooled romosozumab trial data (FRAME + ARCH, combined N=11,273) published in the Journal of Bone and Mineral Research found that the cardiovascular signal was concentrated in the ARCH trial population, which had a higher baseline cardiovascular risk profile than the FRAME population 12. In the FRAME trial, cardiovascular event rates were similar between romosozumab and placebo (1.3% vs. 1.2% at 12 months). This context may be useful in appeals for patients with low cardiovascular risk who are denied on safety grounds.

Romosozumab 210 mg subcutaneously is administered once monthly for 12 doses, followed by transition to an antiresorptive such as alendronate 70 mg weekly or denosumab 60 mg every 6 months, per the Endocrine Society 2020 guideline recommendation for sequential therapy in high-risk patients [10].